☰

Supreet Agarwal, Ph.D. - Publications

Affiliations: 
2013 Pharmacy University of Iowa, Iowa City, IA 
Area:
Pharmacy, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit RF, Coleman I, Lee JK, Nelson PS, Capaldo BJ, et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. The Journal of Clinical Investigation. PMID 37725435 DOI: 10.1172/JCI162148  0.36
2020 Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics. PMID 32371590 DOI: 10.1158/1535-7163.Mct-19-0936  0.422
2019 Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, Beshiri ML, Fang L, Lake RG, Agarwal S, Alilin AN, Xu W, Yin J, Kelly K. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. PMID 31312026 DOI: 10.1038/S41388-019-0873-8  0.42
2018 Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, et al. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports. 8: 17239. PMID 30467317 DOI: 10.1038/S41598-018-35417-0  0.474
2018 Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KA, Yin JJ, Alilin AN, Karzai FH, Dahut W, Corey E, Kelly K. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29748182 DOI: 10.1158/1078-0432.Ccr-18-0409  0.348
2018 Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, McGowen K, Alilin AN, Yin J, Karzai FH, Dahut WL, Corey E, Kelly K. Abstract B051: PDX-derived and patient-derived prostate cancer organoids as a clinically relevant platform for translational research Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B051  0.353
2018 Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Abbey Y, Fang L, Hynes PG, Neil AA, Cawley J, Lake R, Tran C, Tice CM, et al. Abstract B018: A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B018  0.494
2018 Agarwal S, McGowen K, Elloumi F, Cam M, Beshiri M, Jansson K, Corey E, Kelly K. Abstract LB-050: Interferon signaling confers resistance to androgen deprivation therapy in advanced prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-050  0.49
2018 Adelaiye-Ogala RM, Nguyen YT, Rodriguez-Nieves JA, Alilin AN, Agarwal S, Vanderweele D. Abstract 5787: Ipatasertib impairs tumor growth in androgen sensitive and castrate resistant prostate cancer: Evidence in preclinical models Cancer Research. 78: 5787-5787. DOI: 10.1158/1538-7445.Am2018-5787  0.468
2017 Pan H, Jansson KH, Beshiri ML, Yin J, Fang L, Agarwal S, Nguyen H, Corey E, Zhang Y, Liu J, Fan H, Lin H, Kelly K. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget. 8: 77181-77194. PMID 29100379 DOI: 10.18632/Oncotarget.20424  0.385
2017 Jansson KH, Tucker J, Stahl L, Fuller C, Beshiri M, Simmons JK, Agarwal S, Fang L, Alilin AN, Lake R, Tran C, Hynes PG, Cawley J, Yin J, Zhang X, et al. Abstract 3065: High-throughput screen identifies HSP90 as a potential therapeutic target in models of advanced CRPC Cancer Research. 77: 3065-3065. DOI: 10.1158/1538-7445.Am2017-3065  0.303
2017 Agarwal S, McGowen K, Jansson K, Beshiri M, Elloumi F, Cam M, Kelly K. Abstract 2896: STAT1 dependent interferon-related DNA damage resistance signature (IRDS) as a survival mechanism in castrate resistant prostate cancer (CRPC) Cancer Research. 77: 2896-2896. DOI: 10.1158/1538-7445.Am2017-2896  0.321
2016 Jansson KH, Simmons JK, Fuller C, Agarwal S, Hynes PG, Fang L, Lake R, Cawley J, Stahl L, Zhang X, Guha R, Thomas C, Kelly K. Abstract LB-281: Elucidating potential therapeutic targets in a model of Pten/Tp53 null prostate cancer using high-throughput screening technology Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-281  0.443
2016 Agarwal S, Hynes P, Lake R, Fang L, Tillman H, Beshiri M, Jansson K, Karthaus W, Iaquinta P, Sawyers C, Kelly K. Abstract LB-276: The identification and characterization of prostate adenocarcinoma tumor initiating cells Cancer Research. 72. DOI: 10.1158/1538-7445.Am2016-Lb-276  0.432
2015 Agarwal S, Hynes PG, Tillman HS, Lake R, Abou-Kheir WG, Fang L, Casey OM, Ameri AH, Martin PL, Yin JJ, Iaquinta PJ, Karthaus WR, Clevers HC, Sawyers CL, Kelly K. Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Reports. 13: 2147-58. PMID 26628377 DOI: 10.1016/J.Celrep.2015.10.077  0.451
2013 Alqudah MA, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken TC, Assem M. NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR. Plos One. 8: e77299. PMID 24143218 DOI: 10.1371/Journal.Pone.0077299  0.738
2013 Agarwal S, Al-Keilani MS, Alqudah MA, Sibenaller ZA, Ryken TC, Assem M. Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma. Plos One. 8: e62852. PMID 23696788 DOI: 10.1371/Journal.Pone.0062852  0.738
2013 Al-Keilani M, Agarwal S, Alqudah M, Sibenaller Z, Ryken T, Assem M. Abstract 2194: Tyrosyl DNA phosphodiesterase I is a prognostic factor and its inhibition synergizes response to topoisomerase poisons in malignant glioma. Cancer Research. 73: 2194-2194. DOI: 10.1158/1538-7445.Am2013-2194  0.716
2013 Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... Agarwal S, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176  0.666
2012 Assem M, Sibenaller Z, Agarwal S, Al-Keilani MS, Alqudah MA, Ryken TC. Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. Omics : a Journal of Integrative Biology. 16: 113-22. PMID 22401657 DOI: 10.1089/Omi.2011.0031  0.728
2012 Agarwal S, Sibenaller Z, Ryken TC, Assem M. Abstract 2666: Receptor protein tyrosine phosphatase type kappa is a prognostic marker, essential for regulating malignant behavior of glioma cells Cancer Research. 72: 2666-2666. DOI: 10.1158/1538-7445.Am2012-2666  0.758
2010 Assem M, Sibenaller Z, Agarwal S, Al-Keilani M, Alqudah M, Marner J, Ryken TC. Abstract 1283: Chromosome 19 amplification and the consequent NOTCH and VEGF pathways over-activation are associated with malignant glioma poor outcome Cancer Research. 70: 1283-1283. DOI: 10.1158/1538-7445.Am10-1283  0.738
Show low-probability matches.